In the SHR experiment, statistically significant reduction of -21.5 mmHg for Val-Tyr was observed at a lower oral dose (1 mg/kg of body weight), as shown in Table 1. Table 1. Effect of Oral Administration of Peptide on Systolic Blood Pressure in SHR
Sample
| Dose (mg/kg)
| Systolic blood pressure (mmHg) b
| Before administration | Time after administration (h)
| 3
| 6
| 9
| Control
|
| 211.4 ± 8.4
| 218.3 ± 6.0
| 209.6 ± 4.8
| 210.1 ± 4.9
| Val-Tyr
| 0.1 | 241.9 ± 3.7
| 239.9 ± 5.2
| 237.4 ± 2.1
| 231.6 ± 3.9
| 1 | 228.2 ± 3.4
| 220.4 ± 6.2
| 220.0 ± 7.6
| 206.7 ± 9.5* | 10 | 216.6 ± 3.6
| 214.3 ± 1.5
| 216.6 ± 4.1
| 198.9 ± 4.3
| Captopril a
| 1
| 238.7 ± 6.9
| 222.2 ± 3.9*
| 221.1 ± 4.0*
| 224.9 ± 4.1* | a Captopril as a positive control. b Systolic blood pressure is shown as mean ± SE, n = 6. * Significantly different from the before administration at p < 0.05 by paired t test. ** Significantly different from the before administration at p < 0.01 by paired t test.
| |